A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Netupitant/palonosetron (Primary) ; Ondansetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Helsinn Healthcare SA
- 04 Apr 2025 New trial record